25 September
2024
Polarean Imaging
plc
("Polarean" or the "Company")
Virtual Investor
Day
Polarean Imaging plc (AIM: POLX), a
commercial-stage medical device leader in advanced Magnetic
Resonance Imaging ("MRI") of lung function, announces
it will be hosting a virtual investor day on Wednesday 9 October
2024, at 2.00pm BST / 9.00am EST.
The event will be held via a Zoom webinar and
will feature presentations on Polarean's lung functional Xenon MRI
platform, its clinical use and future utility, as well as the
Company's commercial strategy and future plans. The event is open
to all.
A welcome and introduction will be given by
Christopher von Jako, Ph.D., CEO
of Polarean Imaging. The afternoon will also feature
presentations by:
·
Dr. Chase Hall, Chief Medical Advisor
·
Dr. Bastiaan
Driehuys, Chief Scientific Officer and founder of
Polarean
·
Alex Dusek, Chief
Commercial Officer
The presentations will be followed by a Q&A
session where attendees can submit questions to the management
team.
To register for the webinar, please use this link:
Webinar Registration - Zoom
Enquiries:
|
Polarean
Imaging plc
|
www.polarean.com
/ www.polarean-ir.com
|
|
Christopher von Jako, Ph.D., Chief Executive
Officer
|
Via Walbrook PR
|
|
Charles Osborne, Chief Financial
Officer
|
|
|
|
|
|
Stifel (NOMAD
and Sole Corporate Broker)
|
+44 (0)20 7710
7600
|
|
Nicholas Moore / Nick Harland / Ben
Good
|
|
|
|
|
|
Walbrook
PR
|
Tel: +44 (0)20 7933
8780 or polarean@walbrookpr.com
|
|
Anna Dunphy / Phillip Marriage
|
Mob: +44 (0)7876 741
001 / +44 (0)7867 984 082
|
|
|
|
|
|
| |
About Polarean
Polarean is a revenue-generating
medical imaging technology company revolutionising pulmonary
medicine through direct visualisation of lung function by
introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern
solutions to accurately assess lung function. The Company strives
to optimise lung health and prevent avoidable loss by illuminating
hidden disease, addressing the global unmet medical needs of more
than 500 million patients worldwide suffering from chronic
respiratory disease. Polarean is a leader in the field of
hyperpolarisation science and has successfully developed the first
and only hyperpolarised Xenon MRI inhaled contrast agent,
XENOVIEW®, which is
now FDA-approved in the United States. Polarean is dedicated to
researching, developing, and commercialising innovative imaging
solutions with its non-invasive and radiation-free pulmonary
functional MRI platform. This comprehensive drug-device platform
encompasses the proprietary Xenon gas blend, gas hyperpolarisation
system, as well as software and accessories, facilitating fully
integrated modern respiratory imaging operations. Founded in 2012,
with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its
XENOVIEW MRI technology platform. For the latest news and
information about Polarean, please
visit www.polarean.com.
XENOVIEW IMPORTANT
SAFETY INFORMATION
Indication
XENOVIEW®, prepared from the Xenon Xe 129 Gas Blend,
is a hyperpolarized contrast agent indicated for use with magnetic
resonance imaging (MRI) for evaluation of lung ventilation in
adults and pediatric patients aged 12 years and older.
Limitations of
Use
XENOVIEW has not been evaluated for use with lung
perfusion imaging.
CONTRAINDICATIONS
None.
Warnings and
Precautions
Risk of Decreased Image Quality from Supplemental
Oxygen: Supplemental oxygen administered simultaneously with
XENOVIEW inhalation can cause degradation of image quality. For
patients on supplemental oxygen, withhold oxygen inhalation for two
breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.
Risk of Transient Hypoxia: Inhalation of an anoxic
gas such as XENOVIEW may cause transient hypoxemia in susceptible
patients. Monitor all patients for oxygen desaturation and symptoms
of hypoxemia and treat as clinically indicated.
Adverse
Reactions
Adverse Reactions in Adult Patients: The adverse
reactions (> one patient) in efficacy trials were oropharyngeal
pain, headache, and dizziness. Adverse Reactions in Pediatric
and Adolescent Patients: In published literature in pediatric
patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness,
tingling, dizziness, and euphoria. In at least one published study
of pediatric patients aged 6 to 18 years, transient decrease in
SpO2% and transient increase in heart rate was reported following
hyperpolarized xenon Xe 129 administration. XENOVIEW is not
approved for use in pediatric patients less than 12 years of
age.
Please see full prescribing information at
www.XENOVIEW.net